Proactive Investors - Run By Investors For Investors

OptiBiotix’s SlimBiome gathers steam as subsidiary eyes potential IPO

Life sciences firm OptiBiotix Health plc (LON:OPTI) has clinched a number of deals for its SlimBiome weight loss product as the company eyes up a potential initial public offering (IPO). Founder and CEO Stephen O'Hara tells Proactive London how OptiBiotix is changing from an R&D company to a business with greater commercial focus with a number of new deals in 2019 and our prodcuts migrating into other territories.
The group has just inked an agreement with Indian firm Zeon Lifesciences Ltd, granting it an exclusive licence to manufacture and supply SlimBiome in the return in return for a 50% share of the profits.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use